Mydecine Innovations Group Inc. (MYCOF)
Chart Events
Performance Outlook
| Previous Close | 0.6890 |
| Open | 0.5725 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.5724 - 0.6107 |
| 52 Week Range | 0.0010 - 2.4500 |
| Volume | |
| Avg. Volume | 15,811 |
| Market Cap | 3.105M |
| Beta (5Y Monthly) | 3.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.6810 |
| Earnings Date | May 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 140.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MYCOF
Related Research
- MYDECINE INNOVATIONS GROUP INCAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat3 days agoMorningstar
- GlobeNewswire
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructureDENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been speci
- GlobeNewswire
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The Investigator Initiated trial is funded by a near $4 million grant
- GlobeNewswire
Mydecine Provides Company Update; Welcomes New Board Member
DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today provided an update on clinical trial and drug development initiatives, and appointed a new member to its Board of Directors. Corporate Update "As we near the end of the second quarter, I’m proud of the progress our team has made despite the volatile an
